![Niels Jonas Heilskov Graversen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Niels Jonas Heilskov Graversen
Directeur Général chez Affinicon ApS
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Holger Jon Møller | M | - |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark.
University of Aarhus
| 20 ans |
Søren Kragh Moestrup | M | - |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark.
University of Aarhus
| 11 ans |
Jens Kristian Damsgaard | M | - |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | - |
Søren Møller | M | 56 |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | 8 ans |
Lars Henrik Fugger | M | 64 |
University of Aarhus
| 28 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Line Christa Amanda Sørensen | F | 49 |
University of Aarhus
| 7 ans |
Rune Róin | M | - |
University of Aarhus
| 5 ans |
Henrik Andersen | M | 56 |
University of Aarhus
| 9 ans |
Rune Hansen | M | - |
University of Aarhus
| 6 ans |
Martin Lippert | M | 57 |
University of Aarhus
| 5 ans |
Karsten Breum | M | 51 |
University of Aarhus
| 4 ans |
Milan Zdravkovic | M | 54 |
University of Aarhus
| 11 ans |
Gian Luca Cattani | M | 55 |
University of Aarhus
| 4 ans |
Casper Blaase Johansen | M | 49 |
University of Aarhus
| 6 ans |
Ulrik Thagesen | M | 53 |
University of Aarhus
| 1 ans |
Anders Lonning-Skovgaard | M | 52 |
University of Aarhus
| 1 ans |
Morten Beck Jørgensen | M | - |
University of Aarhus
| 1 ans |
Mikael Andreas Geday | M | 56 |
University of Aarhus
| 3 ans |
Jan Fuhr Miller | M | 54 |
University of Aarhus
| 1 ans |
Poul Bendix Kristensen | M | - |
University of Aarhus
| 7 ans |
Ole Groth | M | - |
University of Aarhus
| 5 ans |
Anders Hagh | M | 48 |
University of Aarhus
| 1 ans |
Nikolai Kronborg | M | 52 |
University of Aarhus
| 1 ans |
Kasper Støy | M | - |
University of Aarhus
| 2 ans |
Jan Nielsen | M | 50 |
University of Aarhus
| 1 ans |
Ricco Larsen | M | - |
University of Aarhus
| 6 ans |
Anders Weihrauch | M | - |
University of Aarhus
| 3 ans |
Stenkil Ole | M | 51 |
University of Aarhus
| 5 ans |
Dorthe Berntsen | M | 62 |
University of Aarhus
| 3 ans |
Peter la Cour Gormsen | M | 50 |
University of Aarhus
| 1 ans |
Nauja Bianco | F | - |
University of Aarhus
| 3 ans |
John Petersen | M | - |
University of Aarhus
| 6 ans |
Mogens Thorninger | M | - |
University of Aarhus
| 5 ans |
Tina Høgsted Svanberg | F | - |
University of Aarhus
| 4 ans |
John Sommer Schmidt | M | 51 |
University of Aarhus
| 4 ans |
Steffen Sørensen | M | - |
University of Aarhus
| 4 ans |
Karl Møller Bek | M | - |
University of Aarhus
| 3 ans |
Kristian Villumsen | M | 54 |
University of Aarhus
| 1 ans |
Niels Hobolt | M | - |
University of Aarhus
| 1 ans |
Ellen Nikoline Bjerg Felding | F | - |
University of Aarhus
| 1 ans |
Dan Wejse | M | - |
University of Aarhus
| 4 ans |
Alex Haahr Gouliaev | M | 58 |
University of Aarhus
| 3 ans |
Magnus Olafsson Corfitzen | M | 49 |
University of Aarhus
| 1 ans |
Morten Brøgger | M | 55 |
University of Aarhus
| 1 ans |
Guðmundur Ólason | M | 52 |
University of Aarhus
| 1 ans |
Katja Nowak Nielsen | F | 50 |
University of Aarhus
| 2 ans |
Asmus Rotne | M | 50 |
University of Aarhus
| 4 ans |
Theis Rauhe | M | - |
University of Aarhus
| 3 ans |
Hans-Peter Torsten Ekre | M | 74 |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
Kristian R. Krüger | M | - |
University of Aarhus
| 4 ans |
Eskil Söderlind | M | 65 |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
Henrijette Richter | M | 53 |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
Peter Buhl Jensen | M | 69 |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | 1 ans |
Jakob Bardram | M | 56 |
University of Aarhus
| 3 ans |
Jørn Frederik Falch | M | - |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
Søren Steen Pedersen | M | - |
University of Aarhus
| 2 ans |
Henriette Schütze | F | 56 |
University of Aarhus
| 1 ans |
Truls Kristian Hauger | M | 52 |
University of Aarhus
| 2 ans |
Morten Kierkegaard | M | 54 |
University of Aarhus
| 1 ans |
Karsten Munk Knudsen | M | 53 |
University of Aarhus
| 1 ans |
Carsten Fensholt | M | 62 |
University of Aarhus
| 4 ans |
Jacob Vittrup | M | 53 |
University of Aarhus
| 1 ans |
Bjarke Brøns | M | 49 |
University of Aarhus
| 1 ans |
Jens Ensted Danielsen | M | 50 |
University of Aarhus
| 1 ans |
Nanna Liebach Lüneborg | M | 49 |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | - |
Anders Lund | M | 51 |
University of Aarhus
| 4 ans |
Lars Lose | M | - |
University of Aarhus
| 6 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Danemark | 67 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Niels Jonas Heilskov Graversen
- Réseau Personnel